[Angiotensine Receptor-Neprilysin Inhibitor combination is not the preferred medication for patients after acute...

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Acute myocardial infarction (MI) frequently leads to reduced cardiac function and heart failure.
• Standard treatment often involves ACE inhibitors, but newer therapies are being investigated.

Purpose of the Study:

• To compare the efficacy and safety of sacubitril/valsartan (ARNI) versus an ACE inhibitor (ramipril) in patients post-MI.
• To assess the impact on cardiovascular death, rehospitalization, and heart failure-related visits.

Main Methods:

• The PARADISE-MI study randomized 5661 patients with acute MI and reduced ejection fraction to receive either ramipril or sacubitril/valsartan.
• Patients often had concurrent heart failure symptoms and congestion.

Main Results:

• The primary endpoint of a 15% reduction in cardiovascular death, rehospitalization, or extra heart failure visits was not met.
• Symptomatic hypotension occurred in 28.3% of patients on sacubitril/valsartan versus 21.9% on ramipril.

Conclusions:

• Sacubitril/valsartan did not demonstrate superiority over ramipril in this post-MI population.
• Increased symptomatic hypotension necessitates a cautious approach with ARNIs in this setting.
• ACE inhibitors remain a recommended first-choice treatment in the initial weeks following myocardial infarction.